Current Hypertension Reports

, Volume 10, Issue 1, pp 12–18 | Cite as

Severe paroxysmal hypertension (Pseudopheochromocytoma)

Article

Abstract

Paroxysmal hypertension always engenders a search for a catecholamine-secreting pheochromocytoma. Yet 98% of people with paroxysmal hypertension do not have this tumor. The cause and management of paroxysmal hypertension remain a mystery, and the subject of remarkably few papers. This review presents an approach to understanding and successfully treating this disorder. Patients experience symptomatic blood pressure surges likely linked to sympathetic nervous system stimulation. A specific personality profile associated with this disorder suggests a psychological basis, attributable to repressed emotion related to prior emotional trauma or a repressive (nonemotional) coping style. Based on this understanding, three forms of intervention, alone or in combination, appear successful: antihypertensive therapy with agents directed at the sympathetically mediated blood pressure elevation (eg, combined α- and β-blockade or central α-agonists such as clonidine); psychopharmacologic interventions including anxiolytic and/or antidepressant agents; and psychological intervention, particularly reassurance and increased psychological awareness. An appropriately selected intervention can reduce or eliminate attacks in most patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pacak K, Linehan WM, Eisenhofer G, et al.: Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001, 134:315–329.PubMedGoogle Scholar
  2. 2.
    Manger WM, Gifford RW, eds: Clinical and Experimental Pheochromocytoma, edn 2. Malden, MA: Blackwell Science; 1996:4.Google Scholar
  3. 3.
    Mann SJ: Severe paroxysmal hypertension. An autonomic syndrome and its relationship to repressed emotions. Psychosomatics 1996, 37:444–450.PubMedGoogle Scholar
  4. 4.
    Mann SJ: Severe paroxysmal hypertension (pseudopheochromocytoma): understanding its cause and treatment. Arch Intern Med 1999, 159:670–674.PubMedCrossRefGoogle Scholar
  5. 5.
    Stein PP, Black HR: A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine 1991, 70:46–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Manger WM, Gifford RW: Pheochromocytoma. In Hypertension: Pathophysiology, Diagnosis, and Management, edn 2. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:2225–2244.Google Scholar
  7. 7.
    Grossman A, Pacak K, Sawka A, et al.: Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci 2006, 1073:332–347.PubMedCrossRefGoogle Scholar
  8. 8.
    Bravo EL, Tarazi RC, Fouad FM, et al.: Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981, 305:623–626.PubMedCrossRefGoogle Scholar
  9. 9.
    Balon R, Ortiz A, Pohl R, Yeragani VK: Heart rate and blood pressure during placebo-associated panic attacks. Psychosom Med 1988, 50:434–438.PubMedGoogle Scholar
  10. 10.
    Kaplan NM: Anxiety-induced hyperventilation. A common cause of symptoms in patients with hypertension. Arch Intern Med 1997, 157:945–948.PubMedCrossRefGoogle Scholar
  11. 11.
    Kosten TR, Mason JW, Gillen EL, et al.: Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder. Psychoneuroimmunology 1987, 12:13–20.Google Scholar
  12. 12.
    Kuchel O, Cusson JR, Larochelle P, et al.: Case report: posture-and emotion-induced severe hypertensive paroxysms with baroreceptor dysfunction. J Hypertens 1987, 5:277–283.PubMedCrossRefGoogle Scholar
  13. 13.
    Aksamit TR, Floras JS, Victor RG, et al.: Paroxysmal hypertension due to sinoaortic baroreceptor denervation in humans. Hypertension 1987, 9:309–314.PubMedGoogle Scholar
  14. 14.
    Kuchel O, Buu NT, Larochelle P, et al.: Episodic dopamine discharge in paroxysmal hypertension. Page’s syndrome revisited. Arch Intern Med 1986, 146:1315–1320.PubMedCrossRefGoogle Scholar
  15. 15.
    Frohlich ED, Tarazi RC, Dustan HP: Hyperdynamic beta-adrenergic circulatory state: increased beta-receptor responsiveness. Arch Intern Med 1969, 123:1–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Streeten DH, Anderson GH Jr, Lebowitz M, et al.: Primary hyperepinephrinemia in patients without pheochromocytoma. Arch Intern Med 1990, 150:1528–1533.PubMedCrossRefGoogle Scholar
  17. 17.
    McNeil JJ, Anderson AE, Louis WJ, Morgan DJ: Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. Br J Clin Pharmacol 1979, 8(Suppl 2):157S–161S.PubMedGoogle Scholar
  18. 18.
    Mann SJ: Neurogenic essential hypertension revisited: the case for increased clinical and research attention. Am J Hypertens 2003, 16:881–888.PubMedCrossRefGoogle Scholar
  19. 19.
    Morgan T: Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994, 26:335–346.PubMedCrossRefGoogle Scholar
  20. 20.
    Mann SJ, Gerber LM: Low dose alpha/beta blockade in the treatment of essential hypertension. Am J Hypertens 2001, 14:553–558.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.New York Presbyterian Hospital-Weill/Cornell Medical SchoolNew YorkUSA

Personalised recommendations